ASBP

Aspire Biopharma Holdings, Inc. (ASBP) Business Model Analysis (2026)

Invetso Score: 4.9/10 — Balanced · Last Updated: 2026-09-01

Revenue Model

Revenue generation remains weak and highly inefficient, with revenue per share at 0.094 and asset turnover at 0.007.

Gross margin is positive at 18.3%, but operating and net margins remain deeply negative, indicating limited monetization quality.

Profitability

Operating profitability is severely negative, with EBIT margin at -64.7% and operating margin at -72.6%.

Net margin is -113.1%, and return on assets is -0.82%, showing the business is still far from sustainable earnings power.

Balance Sheet

Liquidity is strong, with a current ratio of 8.0 and cash ratio of 7.2, suggesting ample near-term coverage.

The company shows no debt on the balance sheet metrics provided, and book value per share of 11.33 exceeds the share price implied by valuation ratios.

Capital Efficiency

Return on invested capital is -0.60%, indicating capital is not being deployed profitably.

Working capital turnover is very low at 0.012, and the cash conversion cycle is highly distorted by extreme inventory and payables days.

Valuation

Valuation appears inexpensive on asset and cash-flow measures, with price-to-book at 0.79 and price-to-operating-cash-flow at -1.30.

However, the negative earnings and cash-flow profile makes earnings-based valuation metrics unreliable.

Overall Score

Sources

  • Company filings (10-K, 10-Q, investor presentations)
  • Financial and market data providers
  • Public news and industry information

🔒 Go Beyond This Framework

This is one of 10 institutional-grade frameworks Invetso runs on Aspire Biopharma Holdings, Inc.. Unlock the complete analysis — SWOT, Economic Moat, Porter’s Five Forces, Management, PESTLE and the Invetso Quality Score.

Create your free account on Invetso →